12 results about "Calcium-binding protein" patented technology

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

The invention discloses an application of a serum protein biomarker in preparation of an auxiliary evaluation reagent related to feline calicivirus infection. The biomarker is long-chain acyl coenzyme A synthetase 4 (ACSL4) or calcium binding protein S100A2. When the expression level of the ACSL4 protein in the serum of the to-be-detected cat is obviously increased relative to the expression level in the control serum of a healthy cat, the FCV infection induced lung injury is indicated; when the expression level of the S100A2 protein in the serum of the to-be-detected cat is obviously reduced relative to the expression level in the control serum of the healthy cat, the FCV infection related oral lesion prognosis is poor. The serum ACSL4 and S100A2 can be used as specific biomarkers of FCV infection, so that the problem of high detection false negative rate caused by high virus variation is solved, the diagnosis accuracy is remarkably improved, and quantitative evaluation on clinical prognosis of FCV infection is realized.

The present invention refers to inhibitors of the S100 calcium- binding protein A9 (S100A9) / S100A8 – Toll Like Receptor 4(TLR4) dimer-receptor axis for use in the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). The present invention further refers to pharmaceutical formulations comprising the said inhibitors. The present invention's use of compounds and pharmaceutical formulations may be advantageously employed in HFpEF by attenuating the deleterious effect on endothelial function and prevention of inflammation, production of reactive oxygen species, apoptosis, senescence and pro-fibrotic phenotype.

An in vitro method for assessing or predicting the response of a human patient to periodontal disease treatment is disclosed. The method is based on the insight that biomarker proteins are determined. Thus, in a saliva sample of a patient, the concentration of a specific combination of proteins is measured. One such combination is hemoglobin subunit delta (Hb-delta) and pyruvate kinase (PK). Another combination is at least two of alpha-1-acid glycoprotein (A1AGP), pyruvate kinase (PK), and matrix metallopeptidase-8 (MMP-8), and keratin-4 (K-4). A third combination is alpha-1-acid glycoprotein (A1AGP), pyruvate kinase (PK), and S100 calcium-binding protein A8 (S100A8). Based on the measured concentrations, at least one value is determined that reflects the joint concentration of this proteins. The at least one value can be indicative of the likelihood that the human patient has or will successfully treat periodontitis. The at least one value can be compared to at least one threshold value that reflects the joint concentration in the same way that is associated with successful treatment of periodontitis. This comparison allows to assess whether the test value is an indication of the periodontal treatment status of the patient.

The invention discloses a layered slow-release composition for promoting calcium absorption and a preparation method thereof, and belongs to the technical field of food, the composition has a core-shell-suspension three-layer embedding structure: a core layer is an oil phase core formed by dissolving fat-soluble vitamins in caprylic and capric triglyceride; a shell layer is a compact protective film formed by Arabic gum on the surfaces of oil drops through interfacial polymerization, calcium ions are preferentially adsorbed through electrostatic interaction to form a Ca < 2 + >-COO <-> complexing layer, and the calcium ions are prevented from migrating into an oil phase; the suspension layer is of a three-dimensional network structure synergistically constructed by xanthan gum and natural pectin in a fruit concentrated solution, the composition realizes spatial isolation and sequential release of vitamins and calcium, the vitamins are quickly released in the gastrointestinal tract 15 minutes before, the calcium is slowly released in 30-60 minutes, the vitamin D can play a role in promoting calcium absorption only after being activated, and the vitamin D can play a role in promoting calcium absorption after being activated. The vitamin D of the composition is released in advance and activates calcium binding protein in intestinal tracts, preparation is made for calcium absorption, the bioavailability of the vitamin D is improved by 35-45%, and the calcium absorption rate reaches 45-52%.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least one of Matrix metalloproteinase-9 (MMP9), S100 calcium-binding protein A8 (S100A8), and Hemoglobin subunit beta (Hb-beta); or of the proteins Matrix metalloproteinase-9 (MMP9) and at least one of S 100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

The present disclosure provides compositions and methods for treating an insulin deficiency (ID) disorder or related symptoms in a subject in need thereof, the compositions comprising S100 calcium binding protein A9 (S100A9), variants or fragments of S100 calcium binding protein A9, and insulin, variants or fragments of insulin.

The invention relates to an application of acidic calcium binding protein S100B in lung injury repair, which detects the expression of the S100B protein family member S100B in the lung epithelium injury repair process, and finds that the expression of the S100B protein family member S100B in a lung airway epithelium injury model induced by a Napthelene drug is obviously increased; after the molecular inhibitor is used, the repairing capability of the lung is obviously hindered. In addition, the molecular weight of the S100B protein is only 10 kDa, and the S100B protein is expressed in cells and extracellular cells, can be used as a small molecule for regulating the immune microenvironment around the airway, and can be combined with arginase Arg1 to recruit anti-inflammatory macrophages to participate in the lung tissue regeneration process. The invention also discloses the effect of the S100B micromolecule on mediating the microenvironment to promote the stem cell function in the lung injury repair model, and provides a new detection method and treatment application means for lung injury diseases.

An in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or severe periodontitis is disclosed. The method is based on determining a selected insight into the concentrations of three biomarker proteins. Thus, in a saliva sample of a patient suffering from periodontitis, the concentrations of pyruvate kinase (PK) and at least two of the following are measured: hemoglobin-beta (Hb-beta), hemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8), and S100 calcium-binding protein A9 (S100A9). Based on the measured concentrations, a value is determined that reflects the joint concentration for the proteins. The value is compared to a threshold value that reflects the joint concentration associated with severe periodontitis in the same way. The comparison allows assessing whether the test value is indicative of the presence of severe periodontitis or mild periodontitis of the patient. Thereby, generally, a test value that reflects a joint concentration that is lower than the joint concentration reflected by the threshold value is indicative of the patient having mild periodontitis, and a test value that reflects a joint concentration that is equal to or higher than the joint concentration reflected by the threshold value is indicative of the patient having severe periodontitis.

The invention discloses a natural compound preparation for improving egg shell quality of laying hens in the later egg laying period, and belongs to the technical field of animal nutrition and feed additives. The preparation consists of genistein with the purity of 98%, origanum essential oil containing 5.5% of carvacrol and 0.15% of thymol, and shell powder. The genistein plays a role through a'regulation-environment-raw material 'triple synergistic mechanism: genistein up-regulates expression of uterine calcium binding protein CaBP-D28k and enhances calcium transport and deposition; the origanum vulgare essential oil maintains intestinal health and optimizes a calcium absorption environment; and the shell powder provides a high-bioavailability calcium source. 8-week animal experiments prove that the preparation can significantly improve the eggshell strength and thickness, and can up-regulate the expression of duodenum and uterus related genes (such as CaBP-D28k, PMCA1b, OVO, OPN and the like). The feed is safe, efficient and free of drug residues, breaks through the limitation of traditional calcium supplement, and is suitable for improving the egg shell quality of laying hens in the later laying period.